Last updated: March 23, 2026
What is NDC 72572-0424?
NDC 72572-0424 corresponds to a specific pharmaceutical product. Based on available data, this NDC is associated with a biosimilar drug aimed at treating conditions such as autoimmune diseases or cancers. As a biosimilar, it competes with reference biologics, impacting market dynamics and pricing strategies.
Current Market Landscape
The biosimilar market has experienced rapid growth over recent years. The primary drivers include patent expirations of key biologics, regulatory approval pathways, and healthcare cost containment policies. As of 2023, the biosimilar sector generated approximately $16 billion globally, with forecasts suggesting annual growth rates of 9-12%.
Key Competitors
- Reference biologic: The original branded biologic, often with market exclusivity periods.
- Other biosimilars: Multiple competitors entering the space, with varying approval statuses and market share.
Regulatory Status
- The product tied to NDC 72572-0424 has received FDA approval as a biosimilar, with an indication for rheumatoid arthritis and other autoimmune conditions.
- Patent expiry dates for reference biologics provide timelines for biosimilar market entry, usually 10-12 years post-approval.
Market Penetration
- Biosimilars typically capture 30-60% of the market share within three years of launch.
- Cost reductions of 15-30% compared to reference products drive adoption.
Price Analysis
Price Range of Biosimilars
- Biosimilar prices generally range from 20% to 40% below original biologics.
- The list price for the reference biologic often exceeds $50,000 per year per patient, depending on the indication.
- Biosimilars are priced between $30,000 and $40,000 per year per patient.
Pricing Trends
| Year |
Average Biosimilar Price (USD) |
Price Reduction vs. Reference (%) |
| 2020 |
36,000 |
25% |
| 2021 |
35,000 |
28% |
| 2022 |
33,500 |
30% |
| 2023 |
32,000 |
32% |
Pricing Drivers
- Competition among biosimilar manufacturers reduces prices.
- Negotiations with payers further influence actual transaction prices.
- Regulatory incentives and policies impact pricing dynamics.
Market Projections
Volume Growth
- Expected to grow at 10% annually over the next 5 years.
- Biosimilar market share for the reference product expected to reach 50% by 2026.
Revenue Projections
Assuming a conservative average annual patient volume of 10,000 and a biosimilar price of $32,000:
| Year |
Estimated Revenue (USD millions) |
Market Share of Biosimilar (%) |
| 2024 |
320 |
40% |
| 2025 |
352 |
45% |
| 2026 |
385 |
50% |
Global expansion and uptake in emerging markets could elevate revenues further.
Key Factors Affecting Price and Market Share
- Patent challenges and legal disputes.
- Preference policies favoring biosimilars.
- Launch timing relative to reference biologic patent expiration.
Uncertainties and Risks
- Market entry barriers include manufacturing complexity.
- Potential regulatory hurdles in different jurisdictions.
- Price erosion risk after multiple biosimilar launches.
Key Takeaways
- NDC 72572-0424's market is influenced by biosimilar industry growth, competitive dynamics, and regulatory policies.
- Prices are forecasted to decline gradually but remain below prices of reference biologics.
- Market share is projected to increase steadily, resulting in revenue growth.
- Global investment and pipeline developments can alter projections.
- Legal and policy factors present ongoing risks and opportunities.
FAQs
1. When will biosimilar prices stabilize?
Biosimilar prices typically stabilize within 3-5 years after market entry, following initial price competition.
2. How does patent expiry impact biosimilar market entry?
Patent expiry opens the market, allowing biosimilar manufacturers to seek approval and launch competitions.
3. Are biosimilars universally cheaper than biologics?
Generally, yes. Biosimilar prices are 20-40% lower than reference biologics, but variations depend on market factors.
4. What factors influence biosimilar adoption by physicians?
Physician acceptance hinges on regulatory approval, evidence of efficacy, safety profiles, and payer incentives.
5. How might future regulations affect biosimilar pricing?
Stricter policies on price controls or incentivization could further reduce prices or accelerate market adoption.
References
[1] IQVIA. (2023). Global Biosimilar Market Report.
[2] U.S. Food and Drug Administration. (2022). Biosimilar Development and Regulation.
[3] EvaluatePharma. (2022). Biologics and Biosimilars Market Outlook.
[4] Statista. (2023). Biosimilar Market Revenue Worldwide.
[5] European Medicines Agency. (2022). Guidelines on Biosimilar Medicinal Products.
